461 related articles for article (PubMed ID: 28302019)
1. The Breakthroughs in Cancer Immune Checkpoint Based Therapy: A Review of Development in Immune Checkpoint Study and its Application.
Huang Y; Liang D; Liu J; Zeng J; Zeng Y
Comb Chem High Throughput Screen; 2017; 20(5):430-439. PubMed ID: 28302019
[TBL] [Abstract][Full Text] [Related]
2. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
3. [Basics of cancer immunotherapy].
Fujioka Y; Nishikawa H
Rinsho Ketsueki; 2016; 57(11):2346-2354. PubMed ID: 27941285
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint blocking antibodies in cancer immunotherapy.
Kyi C; Postow MA
FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
[TBL] [Abstract][Full Text] [Related]
5. [Dendritic cell and cancer immune checkpoint].
Kubo T; Hirohashi Y; Torigoe T
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(5):468-472. PubMed ID: 27795504
[TBL] [Abstract][Full Text] [Related]
6. [Cancer immunotherapy by immuno-checkpoint blockade].
Kawakami Y
Rinsho Ketsueki; 2015 Oct; 56(10):2186-94. PubMed ID: 26458459
[TBL] [Abstract][Full Text] [Related]
7. Update on New Therapies With Immune Checkpoint Inhibitors.
Peterson JJ; Steele-Moses SK
Clin J Oncol Nurs; 2016 Aug; 20(4):405-10. PubMed ID: 27441513
[TBL] [Abstract][Full Text] [Related]
8. Immuno-oncology: Allying forces of radio- and immuno-therapy to enhance cancer cell killing.
Bernier J
Crit Rev Oncol Hematol; 2016 Dec; 108():97-108. PubMed ID: 27931845
[TBL] [Abstract][Full Text] [Related]
9. [Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) in cancer therapy].
Hatae R; Chamoto K
Rinsho Ketsueki; 2016; 57(10):2224-2231. PubMed ID: 27795534
[TBL] [Abstract][Full Text] [Related]
10. [Development of immune checkpoint inhibitors].
Kitano S
Rinsho Ketsueki; 2017; 58(8):966-976. PubMed ID: 28883282
[TBL] [Abstract][Full Text] [Related]
11. Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy.
Torphy RJ; Schulick RD; Zhu Y
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29211042
[TBL] [Abstract][Full Text] [Related]
12. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
[TBL] [Abstract][Full Text] [Related]
13. Active Immunotherapy of Cancer.
Chodon T; Koya RC; Odunsi K
Immunol Invest; 2015; 44(8):817-36. PubMed ID: 26575466
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors: Basics and Challenges.
Li B; Chan HL; Chen P
Curr Med Chem; 2019; 26(17):3009-3025. PubMed ID: 28782469
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.
Pico de CoaƱa Y; Choudhury A; Kiessling R
Trends Mol Med; 2015 Aug; 21(8):482-91. PubMed ID: 26091825
[TBL] [Abstract][Full Text] [Related]
16. Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?
Gerber HP; Sapra P; Loganzo F; May C
Biochem Pharmacol; 2016 Feb; 102():1-6. PubMed ID: 26686577
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications.
Esposito A; Criscitiello C; Curigliano G
Curr Opin Oncol; 2015 Nov; 27(6):445-51. PubMed ID: 26447875
[TBL] [Abstract][Full Text] [Related]
18. Combination of checkpoint inhibitors with other agents as a strategy to improve anti-cancer effect - a glimpse to the future.
Karamouzis MV; Papavassiliou AG
Expert Opin Investig Drugs; 2018 Jul; 27(7):569-572. PubMed ID: 29958097
[TBL] [Abstract][Full Text] [Related]
19. The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy.
Khalil DN; Budhu S; Gasmi B; Zappasodi R; Hirschhorn-Cymerman D; Plitt T; De Henau O; Zamarin D; Holmgaard RB; Murphy JT; Wolchok JD; Merghoub T
Adv Cancer Res; 2015; 128():1-68. PubMed ID: 26216629
[TBL] [Abstract][Full Text] [Related]
20. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.
Tsirigotis P; Savani BN; Nagler A
Ann Med; 2016 Sep; 48(6):428-439. PubMed ID: 27224873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]